Raphael Levy is a Director, Antibody Discovery and Display at Lycia Therapeutics. They is proficient in French, Hebrew and English. Colleagues describe them as "Raphael and his high-performing team, under his leadership, have always delivered on their goals and projects. He can be counted on to deliver fantastic results for the most challenging projects. This is exemplified by the discovery of multiple of allosteric antibodies, including XMetA (licensed to Novo-Nordisk), XOMA 358 in clinical development, and the anti-PTHR antibody currently undergoing partnering by XOMA. " and "Over the years that I have known Raphael he has always shown a passion and drive for his work that has made many of our discussions quite lively and enjoyable. Using his strong background in bacterial cell expression and antibody discovery he added value to XOMA's drug discovery program by engineering a bacterial chaperone. In addition to his scientific skills he has proven himself as a project team leader responsible for the selection of a GPCR antagonist antibody that is currently undergoing in vivo studies."